07:31:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaLarge Cap Helsinki
IndustriLäkemedel & Handel
Orion är en koncern med verksamhet inom läkemedelsindustrin. Bolaget bedriver forskning och utveckling av humana – och veterinära läkemedel, där störst fokus innehas inom sjukdomar som drabbar nervsystemet, samt onkologi och luftvägssjukdomar. Idag återfinns bolagets produkter på global nivå, med störst närvaro inom Norden och övriga Europa. Bolagets huvudkontor ligger i Esbo.


2022-10-20 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-03-23 Årsstämma 2022
2022-02-10 Bokslutskommuniké 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-07-19 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning ORNAV 1.50 EUR
2021-03-26 Ordinarie utdelning ORNBV 1.50 EUR
2021-03-25 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-10-21 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-07 Ordinarie utdelning ORNBV 1.50 EUR
2020-05-07 Ordinarie utdelning ORNAV 1.50 EUR
2020-05-06 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-03-26 Ordinarie utdelning ORNBV 1.50 EUR
2020-02-05 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-17 Kvartalsrapport 2019-Q2
2019-04-25 Kvartalsrapport 2019-Q1
2019-03-27 Ordinarie utdelning ORNBV 1.50 EUR
2019-03-27 Ordinarie utdelning ORNAV 1.50 EUR
2019-03-26 Årsstämma 2019
2019-02-06 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-18 Kvartalsrapport 2018-Q2
2018-04-24 Kvartalsrapport 2018-Q1
2018-03-21 Ordinarie utdelning ORNBV 1.45 EUR
2018-03-21 Ordinarie utdelning ORNAV 1.45 EUR
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-07-19 Kvartalsrapport 2017-Q2
2017-05-18 Kapitalmarknadsdag 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-03-23 Ordinarie utdelning ORNAV 1.35 EUR
2017-03-23 Bonusutdelning ORNAV 0.2
2017-03-23 Ordinarie utdelning ORNBV 1.35 EUR
2017-03-23 Bonusutdelning ORNBV 0.2
2017-03-22 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-25 Kvartalsrapport 2016-Q3
2016-07-19 Kvartalsrapport 2016-Q2
2016-04-27 Kvartalsrapport 2016-Q1
2016-03-23 Ordinarie utdelning ORNBV 1.30 EUR
2016-03-23 Ordinarie utdelning ORNAV 1.30 EUR
2016-03-22 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-27 Kvartalsrapport 2015-Q3
2015-07-28 Kvartalsrapport 2015-Q2
2015-05-26 Kapitalmarknadsdag 2015
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-25 Ordinarie utdelning ORNAV 1.30 EUR
2015-03-25 Ordinarie utdelning ORNBV 1.30 EUR
2015-03-24 Årsstämma 2015
2015-02-04 Bokslutskommuniké 2014
2014-10-21 Kvartalsrapport 2014-Q3
2014-07-29 Kvartalsrapport 2014-Q2
2014-04-29 Kvartalsrapport 2014-Q1
2014-03-26 Ordinarie utdelning ORNBV 1.25 EUR
2014-03-26 Ordinarie utdelning ORNAV 1.25 EUR
2014-03-25 Årsstämma 2014
2014-02-04 Bokslutskommuniké 2013
2013-10-22 Kvartalsrapport 2013-Q3
2013-07-30 Kvartalsrapport 2013-Q2
2013-04-23 Kvartalsrapport 2013-Q1
2013-03-20 Ordinarie utdelning ORNAV 1.30 EUR
2013-03-20 Ordinarie utdelning ORNBV 1.30 EUR
2013-03-19 Årsstämma 2013
2013-02-05 Bokslutskommuniké 2012
2012-10-23 Kvartalsrapport 2012-Q3
2012-07-31 Kvartalsrapport 2012-Q2
2012-05-24 Kapitalmarknadsdag 2012
2012-04-24 Kvartalsrapport 2012-Q1
2012-03-21 Bonusutdelning ORNAV 0.12
2012-03-21 Ordinarie utdelning ORNAV 1.30 EUR
2012-03-21 Ordinarie utdelning ORNBV 1.30 EUR
2012-03-21 Bonusutdelning ORNBV 0.12
2012-03-20 Årsstämma 2012
2012-02-07 Bokslutskommuniké 2011
2011-10-25 Kvartalsrapport 2011-Q3
2011-08-02 Kvartalsrapport 2011-Q2
2011-04-01 Ordinarie utdelning ORNAV 1.20 EUR
2011-04-01 Bonusutdelning ORNAV 0.06
2011-04-01 Ordinarie utdelning ORNBV 1.20 EUR
2011-04-01 Bonusutdelning ORNBV 0.06
2010-03-25 Ordinarie utdelning ORNBV 1.00 EUR
2010-03-25 Ordinarie utdelning
2010-03-25 Bonusutdelning
2010-03-25 Bonusutdelning ORNBV 0.1
2009-03-24 Ordinarie utdelning ORNBV 0.95 EUR
2009-03-24 Ordinarie utdelning
2008-03-26 Ordinarie utdelning ORNBV 1.00 EUR
2007-04-03 Ordinarie utdelning
2007-04-03 Ordinarie utdelning ORNBV 1.00 EUR
2006-03-22 Ordinarie utdelning ORNBV 0.85 EUR
2005-03-22 Ordinarie utdelning ORNBV 0.55 EUR
2005-03-22 Ordinarie utdelning
2004-09-15 Bonusutdelning
2004-09-15 Bonusutdelning ORNBV 2.14
2004-03-23 Ordinarie utdelning ORNBV 1.60 EUR
2004-03-23 Ordinarie utdelning
2003-12-12 Bonusutdelning ORNBV 1.5
2003-12-12 Bonusutdelning
2003-03-23 Ordinarie utdelning
2003-03-23 Ordinarie utdelning ORNBV 0.93 EUR
2002-04-16 Ordinarie utdelning
2002-04-16 Ordinarie utdelning ORNBV 1.10 EUR
2001-03-30 Ordinarie utdelning
2001-03-30 Ordinarie utdelning ORNBV 1.20 EUR
2000-03-31 Ordinarie utdelning ORNBV 1.18 EUR
2000-03-31 Ordinarie utdelning
1999-07-28 Bonusutdelning
1999-07-28 Bonusutdelning
1999-04-09 Ordinarie utdelning
1999-04-09 Ordinarie utdelning
1998-04-21 Ordinarie utdelning
1998-04-21 Ordinarie utdelning
1997-04-22 Ordinarie utdelning
1997-04-22 Ordinarie utdelning
1996-04-23 Ordinarie utdelning
1996-04-23 Ordinarie utdelning
2021-01-18 08:00:00


Orion Animal Health and Vetoquinol expand collaboration – Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania  

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

The U.S. Food and Drug Administration FDA granted approval for Orion’s Clevor®, an eye drop indicated for the induction of vomiting in dogs, in June 2020. Under the terms of the related agreement, Vetoquinol will have the right to sell and market Clevor® (ropinirole) in the USA.

On August 1st  2020, Vetoquinol acquired the rights for the Drontal® and Profender® products in the EU and the UK. Effective January 1st 2021, Orion will have the right to sell and market Vetoquinol’s Drontal® and Profender® products in Finland, Hungary and Romania. Drontal® product range is used for the treatment and control of internal parasites in cats and dogs and Profender® for the treatment and control of internal parasites in cats.

These new distribution agreements expand the current collaboration between the two companies under which Vetoquinol has been distributing Orion Animal Health’s sedative products in several European countries since February 2015.

“I’m very pleased to expand our fruitful collaboration with Vetoquinol and have a trusted partner to distribute the latest approved Orion Animal Health innovation in the USA. Also, it is important for us that we can continue to sell Drontal® and Profender® in our home market Finland and expand the distribution to Hungary and Romania”, says Niclas Lindstedt, Vice President of Orion Animal Health.

“We are delighted to reinforce our partnership with Orion. Our Drontal® and Profender® product ranges will benefit from an efficient distribution network in Finland, Hungary and Romania. Moreover, Vetoquinol is proud to be the veterinary laboratory chosen by Orion to develop this innovative Clevor® (ropinirole) brand in the USA. This is a new milestone in our cooperation that demonstrates Vetoquinol’s strong pharmaceutical capabilities and expertise in this key market”, says Matthieu Frechin, CEO of Vetoquinol.

About Orion
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled pulmonary medication under Easyhaler® device portfolio. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

About Vetoquinol
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in more than 100 countries through to 24 subsidiaries established in Europe, the Americas and the Asia/Pacific, and a global Export division. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At June 30th 2020, Vetoquinol employs 2,401 people.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

Contact persons:


Niclas Lindstedt, Vice President Orion Animal Health, Orion Corporation
Tel. +358 10 426 4116


Fanny Toillon, Investor Relations, Vetoquinol
Tel. +33 (03) 84 62 59 88

Emmanuel Dovergne, Investor and Media Relations, Keima Communication
Tel. +33 (0)1 56 43 44 63

Orion Corporation
Orionintie 1A, FI-02200 Espoo, Finland